Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SunRISe-5: TAR-200 vs Intravesical Chemotherapy in HR-NMIBC
NCT06211764Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2024
- Primary completion
- Nov 2030
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 14
01
Overview
A Phase 3 trial of gemcitabine-releasing intravesical system in non-muscle-invasive bladder cancer (NMIBC), sponsored by Janssen Pharmaceutical. Started Apr 2024; status: active, not recruiting.
02
Drugs
gemcitabine-releasing intravesical system
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06211764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211764.